INTEGRATED SAFETY RESULTS FROM STUDIES OF LJP394 IN SLE PATIENTS
Claudia Hura, MD, et al.
Presented at the
American Society of Nephrology Annual Scientific Meeting
St. Louis, MO
Oct. 27-Nov. 1, 2004
REDUCTIONS IN 24-HOUR URINE PROTEIN LEVELS ASSOCIATED WITH TREATMENT
OF SLE PATIENTS WITH LJP394 IN TWO RANDOMIZED, PLACEBO-CONTROLLED
CLINICAL TRIALS
James A Tumlin, MD, et al.
Presented at the
American Society of Nephrology Annual Scientific Meeting
St. Louis, MO
Oct. 27-Nov. 1, 2004
IMPROVED HEALTH-RELATED
QUALITY OF LIFE (HRQOL) FOLLOWING SUSTAINED REDUCTIONS IN ANTI-DSDNA
ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
AFTER TREATMENT WITH ABETIMUS SODIUM (LJP394)
V Strand, B Crawford
Presented at the
American College of Rheumatology 68th Annual Scientific Meeting
San Antonio, TX
Oct. 16-21, 2004
THE EFFECT OF LJP 394
AND CONCOMITANT IMMUNOSUPPRESSIVE AGENTS ON LEVELS OF ANTI-DSDNA
ANTIBODIES IN SLE PATIENTS
Kenneth R Heilbrunn, et al.
Presented at the
American College of Rheumatology 68th Annual Scientific Meeting
San Antonio, TX
Oct. 16-21, 2004
SMALL MOLECULE INHIBITORS OF SSAO AS THERAPEUTICS FOR INFLAMMATORY
AND AUTOIMMUNE DISORDERS
Luisa Salter-Cid, et al.
Presented at
11th Amine Oxidase Workshop Amine Oxidases: Function and Disfunction
University of St. Andrews, Scotland
July 25-29, 2004
ANTI-DSDNA ANTIBODIES
AND EXACERBATION OF RENAL DISEASE IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS: RESULTS FROM 2 RANDOMIZED CONTROLLED TRIALS [RCTS]
WITH LJP 394
M. D. Linnik, et al.
Presented at the
Annual European Congress of Rheumatology "EULAR 2004"
Berlin, Germany
June 9 –12, 2004
IMPROVED HEALTH-RELATED
QUALITY OF LIFE [HRQOL] FOLLOWING SUSTAINED REDUCTIONS IN ANTI
DS-DNA ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
[SLE] AFTER TREATMENT WITH LJP 394
V. Strand, et al.
Presented at the
Annual European Congress of Rheumatology "EULAR 2004"
Berlin, Germany
June 9 –12, 2004
SUMMARY OF SAFETY RESULTS FROM STUDIES OF LJP 394 IN SLE PATIENTS
S. Bombardieri, et al.
Presented at the
Annual European Congress of Rheumatology "EULAR 2004"
Berlin, Germany
June 9 –12, 2004+
ANTI-DSDNA ANTIBODIES AND EXACERBATION OF RENAL DISEASE IN PATIENTS
WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM 2 RANDOMIZED CONTROLLED
TRIALS [RCTS] WITH LJP 394
Matthew D Linnik, et al.
Presented at the
7th International Lupus Congress
New York, NY
May 9-13, 2004
IMPROVED HEALTH-RELATED
QUALITY OF LIFE (HRQOL) FOLLOWING SUSTAINED REDUCTIONS IN ANTI-DSDNA
ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
AFTER TREATMENT WITH LJP394
V Strand, et al.
Presented at the
7th International Lupus Congress
New York, NY
May 9-13, 2004
SUMMARY OF SAFETY RESULTS
FROM STUDIES OF LJP 394 IN SLE PATIENTS
Mario H Cardiel, et al.
Presented at the
7th International Lupus Congress
New York, New York
May 9-13, 2004
REDUCTIONS IN 24-HOUR
URINE PROTEIN LEVELS ASSOCIATED WITH TREATMENT OF SLE PATIENTS
WITH LJP 394 IN TWO RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND
CLINICAL TRIALS
Mario H Cardiel, et al.
Presented at the
7th International Lupus Congress
New York, New York
May 9-13, 2004
SMALL MOLECULE INHIBITORS
OF SSAO/VAP-1 FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATION
Jun Zhang, et. al
Presented at
Experimental Biology 2004
Washington, DC
April 17-21, 2004
SMALL
MOLECULE INHIBITORS OF SSAO AS THERAPEUTICS FOR INFLAMMATORY AND
AUTOIMMUNE DISORDERS
Luisa Salter-Cid, et al.
Presented at
Immune-mediated Diseases/Anti-inflammation Drug Discovery &
Development World Summit
Baltimore, MD
March 8-10, 2004
|
BETA 2-GLYCOPROTEIN
I BINDS FACTOR XI AND INHIBITS ITS ACTIVATION BY THROMBIN AND FACTOR
XIIA: LOSS OF INHIBITION BY CLIPPED BETA 2-GLYCOPROTEIN I
Shi T, et al.
Published in
Proc Natl Acad Sci U S A. 2004
Volume 101, Issue 11: pp 3939-44
DETECTION AND CHARACTERIZATION OF B CELL EPITOPES ON BETA2-GLYCOPROTEIN
I
KA Cockerill, et al.
Published in
Clinical Immunology 2004
Volume 112:pp 129-135
THERAPEUTIC POTENTIAL OF TOLERAGENS IN THE MANAGEMENT OF
ANTIPHOSPHOLIPID SYNDROME
Cockerill KA, Iverson GM, Jones DS, Linnik MD.
La Jolla Pharmaceutical Company, San Diego, California, USA.
Published in
Biodrugs 2004
Volume 18, Issue 5: pp 297-305
ADVANCES IN UNDERSTANDING WHAT WE MEASURE WHEN DETECTING
ANTICARDIOLIPIN AUTOANTIBODIES
G. Michael Iverson, et al.
Published in
Clinica Chimica Acta 2004
Volume 343, Issue 1-2: pp 37-44
LJP 1082: A TOLERAGEN
FOR HUGHES SYNDROME
JT Merrill
Published in
Lupus 2004
Volume13, Issue 5: pp 335-338
LJP 394 (ABETIMUS SODIUM,
RIQUENT®) IN THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
DJ Wallace; JA Tumlin
Published in
Lupus 2004
Volume 13, Issue 5: pp 323-327
|